1. Sandborn W.J., Feagan B.G., Hanauer S.B., Lochs H., Löfberg R., Modigliani R. et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. - 2002; 122: 512-30.
2. Reinisch W., Rutgeerts P., Panaccione R., D’Haens G., Thakkar R., Yu A. Identifying appropriate dichotomizing points for SES-CD to predict long-term clinical remission for adalimumab - treated patients with Crohn’s disease. J. Crohns Colitis. - 2010; 4: P045
3. Vorob'ev G.I., Khalif I.L. Nespetsificheskie vospalitel'nye zabolevaniya kishechnika. Miklosh. -2008.
4. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature. -2011; 474: 307-17.
5. Gastroenterologiya. Natsional'noe rukovodstvo / Pod red. Ivashkina V.T., Lapinoi T. L. GEOTAR Media. - 2008. - 754 c.